FDA alerts providers on Medline kits tied to BD recall
The FDA alerted healthcare providers about Medline convenience kits containing recalled Becton Dickinson antiseptic applicators, and Medline instructed customers to inspect and quarantine affected stock.
The U.S.
Food and Drug Administration (FDA) alerted healthcare providers regarding Medline Inc. (NASDAQ: MDLN ) convenience kits containing recalled antiseptic applicators manufactured by Becton, Dickinson and Company (NYSE: BDX ).
The regulatory warning follows corrective measures by Medline to address kit components affected by an ongoing medical product recall.
Customer Guidance And Action Required Medline issued communication letters on June 12 and June 20 advising affected customers to inspect and quarantine existing stock immediately.
Healthcare facilities must apply the provided over-labels onto affected kits stating that ChloraPrep components require removal and disposal before clinical use.
Read Also: Medline Distribution Center Fire Creates Near-Term Headwind: Analyst Remaining components within the surgical convenience kits, which contain instruments and pharmaceutical supplies for surgical procedures, may still be utilized safely by medical personnel.
Distributors that resold or transferred affected products are instructed to notify secondary recipients immediately.
The regulatory agency continues to review data on this high-risk device issue while advising ongoing safety monitoring for healthcare facilities.
Packaging Defects And Contamination Risks The alert stems from a BD recall involving lot 4032183 of ChloraPrep Clear 1 mL Single Sterile and lot 4073005 of FREPP Clear 1.5 mL applicators.
Packaging wrinkles in the paper lidding compromised sterile seals, exposing patients to potential microbial contamination.
Additionally, environmental factors enabled fungal growth of Aspergillus penicillioides in impacted lots shipped between March 2024 and June 2024.
Fungal contamination can cause systemic infections, sepsis, catheter removals, and prolonged antifungal therapy.
Uncomplicated exposures require no follow-up, though exposed patients showing symptoms need prompt evaluation.
Current Incident Reports As of August 3, Medline has documented zero severe injuries or deaths tied to the kit issues.
BD similarly reported no adverse event notices related to the recalled applicators.
MDLN Price Action: Medline shares were up 0.61% at $35.71 at the time of publication on Thursday, according to Pro data.
Read Also: Nebius Posts 454% Revenue Growth, FY Guidance Reflects Controversial Vineland Project Photo by T.
Schneider via Shutterstock